在胰腺癌中,DDX18通过转录激活的STAT1表达驱动瘤免疫逃生
Guoying Dong1, Qin Wang2, Mingxin Wen1
1Department of Anatomy, School of Basic Medical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, 250012, China.
Oncogene
|August 24, 2023
概括
胰腺癌 (PDAC) 显示出明显的染色质变化,DDX18 (DEAD-box RNA helicase 18) 的上调与生存率差相关. 抑制DDX18-STAT1通路为PDAC提供了一个新的治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 免疫学 免疫学 免疫学
背景情况:
- 胰腺管道腺癌 (PDAC) 由于瘤异质性,癌症干细胞存活率和免疫逃避在免疫抑制瘤微环境 (TME) 中,表现出对治疗的抗性.
- 与相邻组织相比,PDAC中发生了明显的染色质重塑,这表明表观遗传变化有助于疾病的进展.
研究的目的:
- 研究DEAD-boxRNA酶18 (DDX18) 在PDAC病原发生中的作用及其作为治疗点的潜力.
- 阐明DDX18影响STAT1表达,PD-L1水平和瘤免疫微环境的分子机制.
主要方法:
- 采用多种奥米克分析 (基因组学,表观基因组学,转录基因组学) 来确定PDAC中的关键分子参与者.
- 染色体免疫沉 (ChIP) 试验被用于确定DDX18和H3K27me3在STAT1促进体中的沉积.
- 在临床前模型中,DDX18-STAT1轴的抑制被评估与抗PD-L1疗法结合.
主要成果:
- DDX18在PDAC上升调节,与患者生存率差相关.
- DDX18通过抵消H3K27me3在STAT1促进体中的沉积来促进STAT1的表达,从而调节PRC2复合体的形成.
- DDX18-STAT1轴增强癌症干,调节PD-L1,并导致免疫抑制性TME,特征是T淋巴细胞积累和过度激活.
- 抑制DDX18-STAT1轴,结合抗PD-L1疗法,导致在积极的PDAC模型中持续缓解.
结论:
- DDX18是PDAC的一个关键驱动因素,通过DDX18-STAT1-PD-L1轴促进瘤进展和免疫逃逸.
- 针对DDX18-STAT1通路提供了一个有前途的策略,以克服PDAC的治疗耐药性.
- 涉及DDX18抑制和抗PD-L1免疫疗法的组合疗法为治疗PDAC患者提供了一种新的临床方法.
相关概念视频
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Cancer-Critical Genes II: Tumor Suppressor Genes
7.5K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
7.5K
Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
The JAK-STAT Signaling Pathway
9.0K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
9.0K
PI3K/mTOR/AKT Signaling Pathway
3.7K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.7K
Tumor Progression
6.4K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.4K


